Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study

Abstract Patients with estrogen receptor (ER)‐positive breast cancer are less likely to achieve a pathological complete response (pCR) with neoadjuvant chemotherapy. Neoadjuvant endocrine therapy may be more appropriate than neoadjuvant chemotherapy in these hormone‐sensitive patients. Most patients...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Nobuaki Sato, Norikazu Masuda, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Koji Kaneko, Hiroyuki Yasojima, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, Masakazu Toi
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Wiley 2018-07-01
Saila:	Cancer Medicine
Gaiak:	aromatase inhibitors breast neoplasms Ki67 index neoadjuvant therapy postmenopause tailored therapy
Sarrera elektronikoa:	https://doi.org/10.1002/cam4.1600
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!